Dr. Amer Johri is a Professor in the Department of Medicine, Queen’s University, Kingston, Canada.  He has served on the Boards of the ASE and Canadian Society of Echo, and is the immediate past Chair of the ASE Circulation and Vascular Ultrasound (CAVUS) Council. He is founder of the CINQLab.com and the POCUSjournal.com.

His research focuses on innovation of ultrasound-based techniques to enhance risk stratification. Current thematic areas include:  cardiopulmonary POCUS, screening of special populations such as competitive athletes and women, analysis of vulnerable atherosclerotic carotid plaque through 3D, composition, and novel ultrasound contrast applications.  The CINQ Lab is currently pursuing collaborations in the areas of artificial intelligence for vascular analysis.

He is chair of the ASE guideline for the assessment of carotid arterial plaque by ultrasound.  He also chaired the recent ASE POCUS for COVID-19 Assessment statement.  Dr. Johri is passionate about education and curates the monthly podcast for the JASE- he enjoys receiving feedback or questions by twitter @amerjohri

Dr. Aws Almufleh is an Assistant Professor in the Department of Medicine at Queen’s University and the Physician Lead of the Heart Function Clinic in addition to his role in the Echocardiography Laboratory.

Dr. Almufleh’s clinical and research interests lie in optimizing outpatient management of patients with heart failure with reduced ejection fraction, particularly in light of the rapid expansion of heart failure pharmacotherapy and the increasing challenges of therapeutic inertia. Besides research pursuit, Dr. Almufleh, under the mentorship of Dr. Parvathy Nair from the University of British Columbia, is leading a medical education project aimed at optimizing echocardiography competency training during cardiology fellowship which earned the Canadian Cardiovascular Ultrasound Research Excellence Award for Technology & Education – $50,000 CREATE Grant. He has published over 20 peer-reviewed articles and is a co-investigator of the large-scale randomized controlled trial comparing Milrinone with Dobutamine in the Treatment of Cardiogenic Shock; published in the New England Journal of Medicine in August 2021.